ACTIVE BIOTECH: First Data On Efficacy In ETEC-Vaccine by the End of the Quarter; New Investment in Pharmaceuticals Against Cancer.Business & Health Editors MALMO, Sweden--(BUSINESS WIRE)--Feb. 22, 2000 The Year-end report 1999 from Active Biotech reveals that the first data on efficacy from the phase III studies in Guatemala and Mexico are expected to be presented by the end of the quarter. Securing of all the data in a so-called Clean File is in progress. Since November 1999, our collaboration partner SmithKline Beecham has been conducting the last part of phase III. In all, over 1,500 patients will have participated in the studies. The Year-end report 1999, in full available on our web-page www.activebiotech.com, also reveals that Active Biotech and Pharmacia & Upjohn, P&U, have signed a Letter of Intent concerning to the "TTS (1) See text-to-speech. (2) (Transaction Tracking System) Software that monitors a transaction until completion. In the event of a hardware or software failure, it ensures that the database is brought back to its former state before the attempt to "; Tumor Targeted Superantigens research area. TTS is a cancer therapy where the body's own immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. is selectively directed towards the tumor. Active Biotech will acquire from P&U all of the TTS patents and rights concerning the ongoing development of new candidate drugs within cancer, in the first instance, lung and kidney cancer Kidney Cancer Definition Kidney cancer is a disease in which the cells in certain tissues of the kidney start to grow uncontrollably and form tumors. . Active Biotech in Lund has so far managed the project according to a contract research agreement. According to the agreement P&U will honour payments according to the original research agreement, which means that there is no increase on cash burn for year 2000. Active Biotech's payment for the TTS-project consists in that Active Biotech return the so called -1 Integrin-project, concluded in the agreement from 1998, and that Active Biotech pay a royalty on future TTS-products. P&U maintain a sales option for the USA, Japan with market adjusted milestone and royalty payments to Active Biotech if the option is used. Ongoing clinical phase I/phase II studies, against lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. have during autumn 1999 demonstrated promising effects of TTS therapy. The same substance has the potential to be used in other types of cancer, such as kidney cancer. The product has been developed by the researchers at Active Biotech who have an extensive competence in the area of new effective cancer products based on TTS therapy. New clinical trials in combination with interleukin-2 are planned to begin in the first half of 2001 and product launches against lung and kidney cancer are expected within 4-5 years. Active Biotech AB is a Swedish biotechnology group focused on the research and development of pharmaceuticals and vaccines, our core competence Core competence Primary area of expertise. Narrowly defined fields or tasks at which a company or business excels. Primary areas of specialty. being our knowledge of the human immune system. We have a high quality project portfolio and considerable financial resources. Important products include our Cholera vaccine, a vaccine against tourist diarrhoea (ETEC ETEC enterotoxigenic Escherichia coli. ETEC Enterotoxic Escherichia coli, see there ), innovative drugs against MS (SAIK SAIK Sandvikens Aik ) and cancer (TTS). The turnover of Active Biotech was SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 267 million in 1999. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion